Related Experiment Videos
Malignancy in giant cell tumor of bone
Franco Bertoni1, Patrizia Bacchini, Eric L Staals
1Istituto Ortopedico Rizzoli, Bologna, Italy. franco.bertoni@ior.it
Cancer
|May 7, 2003
Summary
Malignant giant cell tumors are high-grade sarcomas with poor outcomes. Distinguishing primary (PMGCT) and secondary (SMGCT) forms is crucial for diagnosis and treatment, as PMGCT can mimic benign tumors.
Area of Science:
- Orthopedic Oncology
- Surgical Pathology
- Bone Sarcomas
Background:
- Malignant giant cell tumors (GCTs) encompass diverse entities, causing diagnostic confusion.
- Clarifying terminology and defining malignancy features in GCTs is essential.
Purpose of the Study:
- To define clinicopathologic and histologic features of malignancy in GCTs.
- To differentiate primary (PMGCT) and secondary (SMGCT) malignant GCTs.
- To clarify terminology surrounding malignant GCTs.
Main Methods:
- Review of Rizzoli Institute cases of primary and secondary malignant GCTs.
- Analysis of clinicopathologic and histologic data for PMGCT and SMGCT.
- Classification of sarcoma subtypes and outcomes.
Main Results:
- Reported 5 PMGCTs and 12 SMGCTs; half of SMGCTs were postradiation.
- Median patient ages were 62 years for PMGCT and 40 years for SMGCT.
- Histologic types included osteosarcoma, fibrosarcoma, and malignant fibrous histiocytoma; all cases showed poor outcomes, particularly postradiation SMGCT.
Conclusions:
- Malignancies in GCTs are high-grade sarcomas with poor prognosis.
- Distinguishing malignant from benign GCTs is critical.
- SMGCT is typically diagnosed by presentation, while PMGCT can mimic benign GCTs histologically, complicating diagnosis.